[go: up one dir, main page]

MX2022014838A - Métodos para sintetizar farnesil dibenzodiazepinonas. - Google Patents

Métodos para sintetizar farnesil dibenzodiazepinonas.

Info

Publication number
MX2022014838A
MX2022014838A MX2022014838A MX2022014838A MX2022014838A MX 2022014838 A MX2022014838 A MX 2022014838A MX 2022014838 A MX2022014838 A MX 2022014838A MX 2022014838 A MX2022014838 A MX 2022014838A MX 2022014838 A MX2022014838 A MX 2022014838A
Authority
MX
Mexico
Prior art keywords
synthesizing
methods
dibenzodiazepinones
farnesyl
farnesyl dibenzodiazepinones
Prior art date
Application number
MX2022014838A
Other languages
English (en)
Inventor
Bernard Matthew Kiernan
Thomas R Bailey
Binfeng Li
Original Assignee
Amo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amo Pharma Ltd filed Critical Amo Pharma Ltd
Publication of MX2022014838A publication Critical patent/MX2022014838A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

La presente invención está dirigida a medios de síntesis para producir compuestos de farnesil dibenzodiazepinona, incluido AMO-01 (ver formula).
MX2022014838A 2020-05-29 2021-05-28 Métodos para sintetizar farnesil dibenzodiazepinonas. MX2022014838A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031911P 2020-05-29 2020-05-29
PCT/US2021/034786 WO2021243171A1 (en) 2020-05-29 2021-05-28 Methods of synthesizing farnesyl dibenzodiazepinones

Publications (1)

Publication Number Publication Date
MX2022014838A true MX2022014838A (es) 2023-04-10

Family

ID=78722845

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014838A MX2022014838A (es) 2020-05-29 2021-05-28 Métodos para sintetizar farnesil dibenzodiazepinonas.

Country Status (9)

Country Link
US (1) US20230192629A1 (es)
EP (1) EP4157283A4 (es)
JP (1) JP2023527866A (es)
CN (1) CN115835869B (es)
AU (1) AU2021281280A1 (es)
CA (1) CA3179814A1 (es)
IL (1) IL298575A (es)
MX (1) MX2022014838A (es)
WO (1) WO2021243171A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561169A (en) * 2003-01-21 2008-06-30 Thallion Pharmaceuticals Inc Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
US10208001B2 (en) * 2015-06-22 2019-02-19 Universidade De Evora Process for preparing 1,4-dibenzodiazepines via Buchwald-Hartwig chemistry
CN109651376B (zh) * 2017-10-12 2022-06-03 江苏创诺制药有限公司 一种氮杂卓并[5,4,3-cd]吲哚-6-酮化合物的合成方法
EP3760620A4 (en) * 2018-02-23 2022-01-05 Beijing Tide Pharmaceutical Co., Ltd. PRESCRIBER ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
CN110183387A (zh) * 2019-05-09 2019-08-30 新乡医学院 具有抗癌活性的二苯并二氮杂*酮衍生物及其制备方法和应用

Also Published As

Publication number Publication date
CN115835869B (zh) 2025-12-19
JP2023527866A (ja) 2023-06-30
CA3179814A1 (en) 2021-12-02
EP4157283A4 (en) 2024-06-12
AU2021281280A8 (en) 2023-02-16
CN115835869A (zh) 2023-03-21
EP4157283A1 (en) 2023-04-05
US20230192629A1 (en) 2023-06-22
IL298575A (en) 2023-01-01
AU2021281280A1 (en) 2023-01-05
WO2021243171A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2022005726A (es) Sintesis mejorada del compuesto inhibidor de g12c de kras.
MX2022005708A (es) Sintesis mejorada del compuesto inhibidor de g12c de kras.
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2023011282A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
UY39831A (es) Métodos para reducir la producción de metano
MY198177A (en) Method For Obtaining Alcohols From Aldehydes III
MX2022003822A (es) Sintesis de derivados de fosfato.
CR20230123A (es) Síntesis de compuestos de quinazolina
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
MX2022012671A (es) Vacuna terapeutica individualizada contra el cancer.
MX2018014130A (es) Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos.
MX2022007662A (es) Sintesis de compuestos para promover el crecimiento del cabello.
AU2020298092A8 (en) Process for the preparation of CIC-1 chloride channel inhibitors
MX2023011976A (es) Sintesis de compuestos analogos de rapamicina.
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
MX2024009760A (es) Proceso para preparar compuestos de silicio organico.
IL279168B (en) A process for the preparation of eribulin
MX2022014838A (es) Métodos para sintetizar farnesil dibenzodiazepinonas.
MX2023013179A (es) Metodos para elaborar un modulador de hemoglobina.
ZA202203822B (en) Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
MX376203B (es) Un proceso novedoso para la sintesis de 1-aril-1-trifluoro-metil-ciclopropanos.
MX2023004950A (es) Proceso para purificacion de pleuromutilinas.
EP4357328A3 (en) Synthesis of (e)-1,1,1,4,5,5,5-heptafluoro-4-(trifluoromethyl)pent-2-ene
MX2021008323A (es) Preparacion de 5-aril pentanoles.
MX2019000984A (es) Proceso para preparacion de indanonas.